3SBio Inc (1530)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 22 Oct 2026
Key indicators
| Last close | HKD 13.63 |
|---|---|
| 52-week range | 13.46 – 35.42 |
| Return, 1 month / 3 months | −18.7% / −21.2% |
| Return, 1 year / 3 years | −49.8% / +127.9% |
| Trend | Below its 200-day average |
| RSI (14) | 32 |
| Volatility (1 year) | 57.8% |
| Worst drawdown (1 year) | -59.8% |
| Average daily value traded | 353.57M HKD |
| Dividend yield | 1.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
3SBio Inc is a biopharmaceutical company based in Shenyang, China, that develops, manufactures and markets protein-based medicines. Its products include recombinant human thrombopoietin for patients with low platelet counts, a biosimilar etanercept for autoimmune conditions, and treatments for kidney disease and diabetes. The company sells to hospitals and healthcare providers, mainly in China, and also works with partners in other markets. Its work centres on biologics for oncology, nephrology and autoimmune disease.
3SBio Inc trades under the code 1530 on the Hong Kong Stock Exchange in Hong Kong, with its price quoted in Hong Kong dollars (HKD). Our dividend records, which start in 2019, show payments in 5 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
3SBio Inc (1530) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 13.63 on 22 October 2026.
Its price-based Market X-Ray is 39 out of 100 (a weak price profile), ranking 1,789 of 2,611 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 49.8% and over the last three months it fell 21.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 23 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -30.4% | ||
| From 52-week high | -60.4% | ||
| Momentum | 20 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -21.2% | ||
| 6-month return | -43.5% | ||
| 12-month return, skipping the last month | -38.3% | ||
| Stability (higher is calmer) | 40 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 57.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -59.8% | ||
| Liquidity | 96 · Strong | Trades actively. | |
| Average daily value traded | 353.57M HKD | ||
| Zero-volume days | 0.0% | ||
| Income | 37 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.8% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −5.1% |
|---|---|
| 1 month | −18.7% |
| 3 months | −21.2% |
| 6 months | −43.5% |
| 1 year | −49.8% |
| 3 years | +127.9% |
| 5 years | +99.2% |
Signals
| 50-day / 200-day average | 16.11 / 19.58 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.69 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 21 Jul 2026 | HKD 0.2500 |
| 21 Jul 2025 | HKD 0.2500 |
| 22 Jul 2024 | HKD 0.2500 |
| 27 Jun 2023 | HKD 0.1000 |
| 27 Jun 2022 | HKD 0.2000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.